Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec:21:75-80.
doi: 10.1016/j.coviro.2016.08.003. Epub 2016 Sep 3.

In vivo tissue-tropism of adeno-associated viral vectors

Arun Srivastava  1
Affiliations
Review

In vivo tissue-tropism of adeno-associated viral vectors

Arun Srivastava. Curr Opin Virol. 2016 Dec.

Abstract

In this review, a brief account of the historical perspective of the discovery of the first cellular receptor and co-receptor of the prototype adeno-associated virus serotype 2 (AAV2) will be presented. The Subsequent discovery of a number of AAV serotypes, and attempts to identify the cellular receptors and co-receptors for these serotype vectors has had significant implications in their use in human gene therapy. As additional AAV serotypes are discovered and isolated, a detailed understanding of their tropism is certainly likely to play a key role in all future studies, both basic science as well as clinical.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic representation of the use of recombinant AAV serotype vectors in various animal models and in humans
Schematic representation of the most commonly used animal models for evaluating the efficacy and safety of recombinant AAV serotype vectors. Various routes of administration of AAV vectors to target various tissues and organs have been utilized. In several Phase I/II, and one Phase III, clinical trials in humans with various AAV serotype vectors to target the indicated organs are also depicted.
See this image and copyright information in PMC

References

    1. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149(3685):754–756. This paper, and the next three papers, describe the first succesful use of recombinant AAV2 vectors to achieve clinical efficacy in Phase I trials in patients with Leber’s congenital amaurosis. - PubMed
    1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2231–2239. - PubMed
    1. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105(39):15112–15117. - PMC - PubMed
    1. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase i trial. Hum Gene Ther. 2008;19(10):979–990. - PMC - PubMed
    1. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–2248. - PMC - PubMed

Publication types

Substances